Dr. John Cush RheumNow
5 years 3 months ago
Popular article: Best Interventions for Gout Flares
https://t.co/duhEHJG9eY https://t.co/tJRwuMPhUR
Dr. Jack Cush talks on education, engagement and the challenge of speaking up, if not first!
Dr. John Cush RheumNow
5 years 3 months ago
Is there a correlation between Vitamin D in RA?
https://t.co/QXYVsa5jzP https://t.co/bH5OtL7Dig
Dr. John Cush RheumNow
5 years 3 months ago
Watch: Sex Differences in Autoimmune Disease Susceptibility: Drs. Yusof and Robinson
https://t.co/rvva90SQfg https://t.co/evYgTUCS1V
B-cells play a major role in the pathogenesis of primary Sjogren’s syndrome (pSS) through antibody-dependent and antibody-independent functions, as well as evident by progression to B-cell malignancies/lymphoma. Hence, targeting B-cell is attractive. Despite efficacy of B-cell depleting therapy with rituximab in Phase II trials and case series, it failed to meet its primary endpoint when investigated in two Phase III trials. It is worth noting
Dr. John Cush RheumNow
5 years 3 months ago
RA ILD: Stepping out of the shadows
Interstitial lung disease (ILD) is a common complication of rheumatoid arthritis (RA) with up to 8% of patients affected with clinically significant ILD.
https://t.co/BaoqQLKR5C https://t.co/duIqHVfCAa
Dr. John Cush RheumNow
5 years 3 months ago
Our "Best of EULAR" podcast is available for download.
https://t.co/dOqNum7nFr https://t.co/WW8wJUKOj7
Dr. John Cush RheumNow
5 years 3 months ago
When should you use a JAK inhibitor in RA?
Dr. Janet Pope ( @Janetbirdope ) shares #EULAR2021 presentations.
https://t.co/qF2tjQXLk1 https://t.co/AqJ1dMWV3t
Dr. John Cush RheumNow
5 years 3 months ago
How do we measure success in lupus?
Dr. Kathryn Dao ( @KDAO2011 ) discusses abstract OP0296, "The 2021 DORIS Definition of Remission in SLE - Final Recommendations From an International Task Force", presented at the #EULAR2021 meeting.
https://t.co/7thqrfIqnL https://t.co/iXKfcbtDfv
Multiple studies compared effectiveness, retention and/or safety of biological DMARDs (bDMARDs) and JAK inhibitors (JAKi) at EULAR 2021. But be careful of what you read because depending on age, gender, comorbidities, line of therapy and access to treatment, you may find highly variable results.
It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.
